Navigation Links
At the 2007 Alzheimer's Association International Conference on the,Prevention of Dementia - Neurochem's U.S. Principal Investigator,Presents Update on Tramiprosate (Alzhemed)

WASHINGTON, DC, June 11, 2007 /PRNewswire-FirstCall/ - Paul S. Aisen, M.D., Professor of Neurology and Medicine at Georgetown University Medical Center, and principal investigator in the United States of Neurochem Inc.'s North American Phase III clinical trial for tramiprosate (ALZHEMED(TM)) will present today an update on Neurochem's investigational product candidate for the treatment of Alzheimer's disease (AD). The presentation by Dr. Aisen will take place at the Intervention and Treatment Session, scheduled from 2:30 - 4:30 P.M. (ET), at the Alzheimer's Association International Conference on Prevention of Dementia in Washington, DC. In his presentation entitled, A Phase III Study of the Efficacy, Safety and Disease Modification Effect of Tramiprosate in Mild-to-Moderate Alzheimer's Disease, Dr. Aisen will review the Phase III clinical trial and provide an update.

Neurochem announced in April 2007 that an adjustment to the initial statistical model, as set out in the statistical plan, would be necessary to provide accurate results. The procedure to arrive at a reliable model involves a detailed analysis of potential confounding factors, and Dr. Aisen will present on the progress to date. In addition, Dr. Aisen will provide an update on the progress in the analysis of the Phase III clinical trial primary endpoint data. Some preliminary descriptive data shows numerical differences in favor of tramiprosate (ALZHEMED(TM)) on the primary clinical endpoint and also shows differences between groups on the primary disease modification endpoint as measured by magnetic resonance imaging (MRI). However, work regarding the adjustment of the statistical model is ongoing and, therefore results of the Phase III clinical trial cannot be derived from the preliminary data nor can statistical significance be assigned at this time. Accordingly, no predictions or conclusions can yet be made regarding the outcome of the Phase III study.






Page: 1 2 3 4

Related medicine technology :

1. Samaritans Alzheimers Drug Caprospinol Suggests Brain May be Able to Heal From Alzheimers Disease
2. Resveratrol Studies Suggest Broad Implications for SIRT1 Activation in Neurodegenerative Diseases of Aging Such as Alzheimers Disease
3. Accera, Inc. Announces Open-Label Data from Phase II Study in Alzheimers Disease at International Conference on Prevention of Dementia
4. Myriad Genetics Presents Mathematical Comparison of Disease Modification Trial Designs at Alzheimers ConferenceCurrent Flurizan Phase 3 Study Design May Demonstrate Disease Modification
5. Treating Heart Disease Risk Factors May Slow Alzheimers Disease Progression
6. Medivations Dimebon Maintains Statistically Significant Benefit on All Five Efficacy Endpoints in Alzheimers Disease Trial After One Year of Therapy
7. Clinical Update - Debio 9902 (ZT-1) for Alzheimers Disease
8. Medivation to Host Conference Call to Discuss Top-Line 12-Month Results From Dimebon Alzheimers Disease Study
9. Medivation Announces Presentation of New Subset Analyses From Dimebon Phase 2 Alzheimers Disease Trial at American Academy of Neurology Annual Meeting
10. Ceregene Presents Interim Phase 1 Clinical Data of CERE-110 for the Treatment of Alzheimers Disease
11. Samaritan Announces Positive Data in Nonclinical (IND) In-Vitro Studies for Promising Alzheimers Drug
Post Your Comments:
(Date:7/11/2014)... 11, 2014 On Thursday, ... 0.52%, the Dow Jones Industrial Average finished the day 0.42% ... down 0.41%. The losses were broad based as eight out ... 500 Health Care Sector Index ended the day at 711.88, ... last one month. Investor-Edge has initiated coverage on the following ...
(Date:7/11/2014)... 2014 Neurelis, Inc. ("Neurelis") today announced an ... option held by Biotie to purchase Neurelis, clearing the ... (intranasal diazepam) for pediatric and adult epilepsy patients who ... year, Biotie has advanced the development program for NRL-1 ... clinical work required for NDA submission to the FDA.  ...
(Date:7/10/2014)... Integrated Silicon Solution, Inc. (Nasdaq: ... IC solutions, today announced that it will host its ... 7:00 a.m. Pacific Time (10:00 a.m. Eastern Time) to ... third quarter ended June 30, 2014. To ... 6:50 a.m. Pacific time on July 24, 2014.  The ...
Breaking Medicine Technology:Health Care Equipment Equities Movers and Shakers -- Research on Covidien, Baxter, DexCom, and Boston Scientific 2Health Care Equipment Equities Movers and Shakers -- Research on Covidien, Baxter, DexCom, and Boston Scientific 3Health Care Equipment Equities Movers and Shakers -- Research on Covidien, Baxter, DexCom, and Boston Scientific 4Neurelis Regains Rights to Intranasal Diazepam Program 2Neurelis Regains Rights to Intranasal Diazepam Program 3
... Nov. 15, 2011 Reportlinker.com announces that ... in its catalogue: ... India & China ... emerging economies represent a combined pharmaceutical market ...
... Pa, Nov. 15, 2011 As any purchasing manager knows, ... shipping options is time lost. When purchasing surgical instruments ... In January of 2010, Robert Edelstein, President of Millennium ... Saints Charities seeking a vendor for eye surgical instruments ...
Cached Medicine Technology:The Outlook for Pharmaceuticals in Brazil, Russia, India & China 2The Outlook for Pharmaceuticals in Brazil, Russia, India & China 3The Outlook for Pharmaceuticals in Brazil, Russia, India & China 4The Outlook for Pharmaceuticals in Brazil, Russia, India & China 5Millennium Surgical Corp. Provides Instruments to Latter Day Saints Charities for Humanitarian Projects 2
(Date:7/12/2014)... “After my mom’s stroke, she loss the use ... loss the use of his left side. Eating became a difficult ... help people like them enjoy eating again,” said an inventor, from ... PATRICIA CAROL HALL PLATE (P C H PLATE). , The PATRICIA ... way to eat for individuals who suffer from stroke, experience tremors ...
(Date:7/12/2014)... With prom shopping reaching its final days, VogueQueen.com, a ... showcase its new and trendy apparels. Recently, the company ... its online shop. Additionally, it is now providing huge ... According to the company’s sales manager, the promotion will ... , He says, “Now, worldwide clients can order cheap ...
(Date:7/12/2014)... 2014 “Critical Care Therapeutics in ... Late-Stage Four-Factor PCCs and Recombinant Products to Drive ... care market in the US, UK, France, Germany, ... an estimation of market size for 2013, along ... care indications that are being treated using the ...
(Date:7/12/2014)... 2014 Utah Valley Entrepreneurial Forum Top ... awards being bestowed to companies in revenue, and pre-revenue ... community with recognition for new ideas as well as ... revenue. , 25 Under 5 highlights outstanding Utah entrepreneurs ... under 5 years old. Award recipients were recognized at ...
(Date:7/12/2014)... 12, 2014 Praeclarus Press ... as a valuable new resource for women in need ... American women work away from their children. Today’s mothers ... benefits of breastfeeding, but often feel unsupported when it ... babies. With its evidence-based insights, and written by Nancy ...
Breaking Medicine News(10 mins):Health News:VogueQueen.com Updates Its Summer Collection With New And Trendy Evening Dresses 2Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 2Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 3Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 4Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 5Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 6Health News:SquareHook is Recognized for UVEF 25 Businesses Under 5 Years-Watch Out 2Health News:Praeclarus Press Announces the Release of Working and Breastfeeding Made Simple by Nancy Mohrbacher, A Much Needed Resource For Today's Working Mothers 2
... with highest levels are more apt to have joint replacement, ... of a certain protein strongly predict the risk of hip ... a new study shows. , The research involved 912 healthy ... led to a knee or hip replacement between 1990 and ...
... /PRNewswire/ - rL Solutions, the leading provider of healthcare ... be sponsoring the 2009 MITSS HOPE Award. MITSS and ... 8th Annual Dinner and Fundraiser on Thursday, November 12, ... MITSS established this award in 2008 to recognize people ...
... , , , ... Francisco SPCA ( www.sfspca.org ), the city,s leading privately supported, ... and safety. , , Whether traveling out of ... The SF/SPCA offers this guide for quick and easy reference: ...
... , , , , ... On Tuesday, Governor Schwarzenegger line-item vetoed the Department of Public Health,s ... domestic violence shelters and centers. , , ... advocacy, assistance with restraining orders, counseling and other vital support services. ...
... R.I., July 30 CVS/pharmacy, the nation,s largest retail pharmacy, announced ... with visual impairments and other disabilities. The Company has installed ... website in 2009. , , ... , Today,s announcement is the result of a ...
... patients (three male and seven female) with hepatic angiomyolipoma, ... 19-78 years). Of these patients, dynamic contrast CT showed ... density, absence of a capsule, and prominent central vessels ... with or without a fat component in four cases ...
Cached Medicine News:Health News:Biomarker Could Predict Severe Osteoarthritis 2Health News:rL Solutions to Sponsor 2009 MITSS HOPE Award 2Health News:The San Francisco SPCA Launches Online Guide for Summer Pet Health & Safety 2Health News:The San Francisco SPCA Launches Online Guide for Summer Pet Health & Safety 3Health News:Governor Eliminates Funding to Domestic Violence Programs 2Health News:CVS/pharmacy Enhancing Accessibility for the Visually Impaired To Its Web Site and Store Point of Sales Devices 2Health News:CVS/pharmacy Enhancing Accessibility for the Visually Impaired To Its Web Site and Store Point of Sales Devices 3Health News:CVS/pharmacy Enhancing Accessibility for the Visually Impaired To Its Web Site and Store Point of Sales Devices 4
Hard protective shields for post-operative or post-injury use. Universal, or Left/Right specific. Packaged 12 per box....
Hard protective shields for post-operative or post-injury use. Universal, or Left/Right specific. Packaged 12 per box....
Hard protective shields for post-operative or post-injury use. Universal, or Left/Right specific. Packaged 12 per box....
... The Wet-Field Coagulator provides precise episcleral, ... peripheral tissue trauma. Controlled Rf diathermy ... comprehensive line of bipolar Eraser instruments, ... enhanced features that ensure a high ...
Medicine Products: